Autologous ovarian tumor antigens

Autologous ovarian tumor antigens comprise the full repertoire of tumor-associated antigens (TAAs) and neoantigens derived directly from a patient's own ovarian malignancy (NCI, 2024; Bobisse et al., 2018). This personalized antigenic profile is utilized in the development of autologous tumor cell vaccines and adoptive cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy, to elicit a specific and multi-targeted immune response (Santoiemma & Powell, 2015). Because ovarian cancer is characterized by significant intra-tumoral and inter-patient heterogeneity, targeting a broad spectrum of autologous antigens helps mitigate the risk of immune escape that often occurs with single-antigen targeted therapies (Bobisse et al., 2018). In clinical practice, these antigens are often processed from surgically resected tumor tissue and may be modified or co-administered with adjuvants like GM-CSF to enhance dendritic cell recruitment and antigen presentation (Gradalis, Inc., 2024). Notable therapeutic candidates like gemogenovatucel-T (Vigil) utilize this approach to improve recurrence-free survival in patients with advanced-stage ovarian cancer by fostering a durable T-cell mediated memory response against the primary tumor's unique molecular signature (Gradalis, Inc., 2024).

Other names

Patient-specific ovarian cancer antigensAutologous tumor-associated antigensSelf-derived ovarian tumor antigensAutologous tumor lysate

Induction of a polyvalent, patient-specific immune response by presenting a broad spectrum of autologous tumor antigens to the immune system, typically via dendritic cell activation or direct T-cell recognition, often enhanced by the expression of immunostimulatory cytokines like GM-CSF (Gradalis, Inc., 2024; NCI, 2024).